Difference between revisions of "Tamoxifen (Nolvadex)"
Jump to navigation
Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type. Tamoxifen has estrogen antagonist properties in breast tissue. It has estrogen agonist properties in bone, helping to decrease bone resorption, but in contrast to [[Raloxifene (Evista)]], it also has agonist properties in uterine tissue.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf Tamoxifen (Nolvadex) package insert]</ref><ref>[ | + | Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type. Tamoxifen has estrogen antagonist properties in breast tissue. It has estrogen agonist properties in bone, helping to decrease bone resorption, but in contrast to [[Raloxifene (Evista)]], it also has agonist properties in uterine tissue.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf Tamoxifen (Nolvadex) package insert]</ref><ref>[[Media:Tamoxifen.pdf | Tamoxifen (Nolvadex) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | *[[Uterine cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf#page=32 Tamoxifen (Nolvadex) package insert PDF pages 32-37]<ref name="insert"></ref> | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf#page=32 Tamoxifen (Nolvadex) package insert PDF pages 32-37]<ref name="insert"></ref> | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/Tamoxifen.aspx Tamoxifen (Nolvadex) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Tamoxifen.aspx Tamoxifen (Nolvadex) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/tamoxifen-patient-drug-information Tamoxifen (Nolvadex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tamoxifen-patient-drug-information Tamoxifen (Nolvadex) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/tamoxifen-patient-drug-information Tamoxifen (Nolvadex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tamoxifen-patient-drug-information Tamoxifen (Nolvadex) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Selective estrogen receptor modulators]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Uterine cancer medications]] | ||
Revision as of 21:26, 14 October 2012
Also known as Istubal, Soltamox, or Valodex.
General information
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type. Tamoxifen has estrogen antagonist properties in breast tissue. It has estrogen agonist properties in bone, helping to decrease bone resorption, but in contrast to Raloxifene (Evista), it also has agonist properties in uterine tissue.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Tamoxifen (Nolvadex) package insert PDF pages 32-37[1]
- Tamoxifen (Nolvadex) patient drug information (Chemocare)[3]
- Tamoxifen (Nolvadex) patient drug information (UpToDate)[4]